BACKGROUND:VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro. METHODS: A randomised, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacodynamics of VX-809 in adult patients with cystic fibrosis (n=89) who were homozygous for the F508del-CFTR mutation. Subjects were randomised to one of four VX-809 28 day dose groups (25, 50, 100 and 200 mg) or matching placebo. RESULTS: The type and incidence of adverse events were similar among VX-809- and placebo-treated subjects. Respiratory events were the most commonly reported and led to discontinuation by one subject in each active treatment arm. Pharmacokinetic data supported a once-daily oral dosing regimen. Pharmacodynamic data suggested that VX-809 improved CFTR function in at least one organ (sweat gland). VX-809 reduced elevated sweat chloride values in a dose-dependent manner (p=0.0013) that was statistically significant in the 100 and 200 mg dose groups. There was no statistically significant improvement in CFTR function in the nasal epithelium as measured by nasal potential difference, nor were there statistically significant changes in lung function or patient-reported outcomes. No maturation of immature F508del-CFTR was detected in the subgroup that provided rectal biopsy specimens. CONCLUSIONS: In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland. Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. CLINICAL TRIAL NUMBER: NCT00865904.
RCT Entities:
BACKGROUND:VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator, has been shown to increase the cell surface density of functional F508del-CFTR in vitro. METHODS: A randomised, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacodynamics of VX-809 in adult patients with cystic fibrosis (n=89) who were homozygous for the F508del-CFTR mutation. Subjects were randomised to one of four VX-809 28 day dose groups (25, 50, 100 and 200 mg) or matching placebo. RESULTS: The type and incidence of adverse events were similar among VX-809- and placebo-treated subjects. Respiratory events were the most commonly reported and led to discontinuation by one subject in each active treatment arm. Pharmacokinetic data supported a once-daily oral dosing regimen. Pharmacodynamic data suggested that VX-809 improved CFTR function in at least one organ (sweat gland). VX-809 reduced elevated sweat chloride values in a dose-dependent manner (p=0.0013) that was statistically significant in the 100 and 200 mg dose groups. There was no statistically significant improvement in CFTR function in the nasal epithelium as measured by nasal potential difference, nor were there statistically significant changes in lung function or patient-reported outcomes. No maturation of immature F508del-CFTR was detected in the subgroup that provided rectal biopsy specimens. CONCLUSIONS: In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland. Additional data are needed to determine how improvements detected in CFTR function secondary to VX-809 in the sweat gland relate to those measurable in the respiratory tract and to long-term measures of clinical benefit. CLINICAL TRIAL NUMBER: NCT00865904.
Authors: J P Clancy; Z Bebök; F Ruiz; C King; J Jones; L Walker; H Greer; J Hong; L Wing; M Macaluso; R Lyrene; E J Sorscher; D M Bedwell Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: M Wilschanski; L L Miller; D Shoseyov; H Blau; J Rivlin; M Aviram; M Cohen; S Armoni; Y Yaakov; T Pugatsch; T Pugatch; M Cohen-Cymberknoh; N L Miller; A Reha; V J Northcutt; S Hirawat; K Donnelly; G L Elfring; T Ajayi; E Kerem Journal: Eur Respir J Date: 2011-01-13 Impact factor: 16.671
Authors: I Bronsveld; F Mekus; J Bijman; M Ballmann; H R de Jonge; U Laabs; D J Halley; H Ellemunter; G Mastella; S Thomas; H J Veeze; B Tümmler Journal: J Clin Invest Date: 2001-12 Impact factor: 14.808
Authors: Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason McCartney; Vijayalaksmi Arumugam; Caroline Decker; Jennifer Yang; Chris Young; Eric R Olson; Jeffery J Wine; Raymond A Frizzell; Melissa Ashlock; Paul Negulescu Journal: Proc Natl Acad Sci U S A Date: 2009-10-21 Impact factor: 11.205
Authors: Rhea P Hudson; P Andrew Chong; Irina I Protasevich; Robert Vernon; Efrat Noy; Hermann Bihler; Jian Li An; Ori Kalid; Inbal Sela-Culang; Martin Mense; Hanoch Senderowitz; Christie G Brouillette; Julie D Forman-Kay Journal: J Biol Chem Date: 2012-06-21 Impact factor: 5.157
Authors: Shyam Ramachandran; Samantha R Osterhaus; Kalpaj R Parekh; Ashley M Jacobi; Mark A Behlke; Paul B McCray Journal: J Biol Chem Date: 2016-10-18 Impact factor: 5.157